Tyra Biosciences, Inc. Investing Cash Flow
Tyra Biosciences, Inc. (TYRA) reported Investing Cash Flow of -$102.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $17.85M, a 14.43% decline year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$120.24M, a 475.46% decline year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $34.38M, a 394.06% increase year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$14.81M, a 168.68% decline year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $72.46M.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$98.40M.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$144.60M.
- Tyra Biosciences, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$559.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$102.39M 10-Q · filed 2026-08-04 | -$68.01M derived: sum of 3 quarters · filed 2026-08-04 | -$82.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$120.24M 10-Q · filed 2026-05-13 | -$85.87M derived: sum of 2 quarters · filed 2026-05-13 | -$100.67M derived: sum of 3 quarters · filed 2026-05-13 | -$79.81M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $34.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $19.57M derived: sum of 2 quarters · filed 2026-03-02 | $40.44M derived: sum of 3 quarters · filed 2026-08-04 | $72.46M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$14.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.06M derived: sum of 2 quarters · filed 2026-08-04 | $38.09M 10-Q · filed 2025-11-05 | $45.04M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $20.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $52.89M 10-Q · filed 2026-08-04 | $59.85M derived: sum of 3 quarters · filed 2026-08-04 | $81.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $32.03M 10-Q · filed 2026-05-13 | $38.98M derived: sum of 2 quarters · filed 2026-05-13 | $60.54M derived: sum of 3 quarters · filed 2026-05-13 | -$84.45M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $28.52M derived: sum of 2 quarters · filed 2026-03-02 | -$116.48M derived: sum of 3 quarters · filed 2026-03-02 | -$98.40M 10-K · filed 2026-03-02 |
| 2024-09-30 | $21.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$123.43M derived: sum of 2 quarters · filed 2025-11-05 | -$105.36M 10-Q · filed 2025-11-05 | -$249.80M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$144.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$126.92M 10-Q · filed 2025-08-14 | -$271.36M derived: sum of 3 quarters · filed 2025-08-14 | -$271.44M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $18.07M 10-Q · filed 2025-05-08 | -$126.36M derived: sum of 2 quarters · filed 2025-05-08 | -$126.45M derived: sum of 3 quarters · filed 2025-05-08 | -$126.49M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$144.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$144.52M derived: sum of 2 quarters · filed 2025-03-27 | -$144.56M derived: sum of 3 quarters · filed 2025-03-27 | -$144.60M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$126.00K derived: sum of 2 quarters · filed 2024-11-07 | -$167.00K 10-Q · filed 2024-11-07 | -$188.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$84.00K 10-Q · filed 2024-08-07 | -$105.00K derived: sum of 3 quarters · filed 2024-08-07 | -$153.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$41.00K 10-Q · filed 2024-05-09 | -$62.00K derived: sum of 2 quarters · filed 2024-05-09 | -$110.00K derived: sum of 3 quarters · filed 2024-05-09 | -$361.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$69.00K derived: sum of 2 quarters · filed 2024-03-19 | -$320.00K derived: sum of 3 quarters · filed 2024-03-19 | -$559.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$299.00K derived: sum of 2 quarters · filed 2023-11-07 | -$538.00K 10-Q · filed 2023-11-07 | -$643.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$490.00K 10-Q · filed 2023-08-10 | -$595.00K derived: sum of 3 quarters · filed 2023-08-10 | -$835.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$239.00K 10-Q · filed 2023-05-04 | -$344.00K derived: sum of 2 quarters · filed 2023-05-04 | -$584.00K derived: sum of 3 quarters · filed 2023-05-04 | -$824.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$345.00K derived: sum of 2 quarters · filed 2023-03-22 | -$585.00K derived: sum of 3 quarters · filed 2023-03-22 | -$645.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | -$240.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$480.00K derived: sum of 2 quarters · filed 2022-11-03 | -$540.00K 10-Q · filed 2022-11-03 | -$607.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$240.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$300.00K 10-Q · filed 2022-08-04 | -$367.00K derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$60.00K 10-Q · filed 2022-05-05 | -$127.00K derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$312.00K 10-K · filed 2022-03-03 | ||
| 2020-09-30 | -$245.00K 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |